The Phase 1b Clinical Trial Focuses on Assessing the Safety and Efficacy of the Two-Drug Combination in a Cancer Associated with Longer Survival to Immunotherapy When Genetically Deficient in PP2A PASADENA, CA, Sept. 20, 2023 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) (“LIXTE”), today announced a Phase 1b collaborative clinical trial to assess whether adding Lixte’s LB-100 to GSK’s programmed death receptor-1 (PD-1)-blocking monoclonal antibody, dostarlimab, may enhance the effectiveness of immunotherapy in the treatment of ovarian clear cell carcinoma (OCCC).

1b期临床试验的重点是评估两种药物联合治疗与PP2A PASADENA，CA，2023年9月20日（GLOBE NEWSWIRE）遗传缺陷时免疫治疗存活时间较长的癌症的安全性和有效性--LIXTE Biotechnology Holdings，Inc。（纳斯达克股票代码：LIXT）（“LIXTE”），今天宣布了一项1b期合作临床试验，以评估将Lixte的LB-100加入GSK的程序性死亡受体-1（PD-1）阻断单克隆抗体dostarlimab是否可以提高免疫疗法治疗卵巢透明细胞癌的有效性（OCCC）。

The clinical trial is sponsored by The University of Texas - MD Anderson Cancer Center and will be conducted at MD Anderson and will also be open at Northwestern University’s Robert H. Lurie Comprehensive Cancer Center. LIXTE will provide LB-100; GSK will provide dostarlimab and financial support for the clinical trial.

该临床试验由德克萨斯大学MD安德森癌症中心赞助，将在MD安德森进行，也将在西北大学的Robert H.Lurie综合癌症中心开放。LIXTE将提供LB-100；GSK将为临床试验提供dostarlimab和财务支持。

The clinical trial is based on the observation of longer survival of patients with OCCC treated with immunotherapy whose cancer cells have an acquired gene mutation resulting in a reduction in PP2A. This finding was reported by the lead clinical investigators of this new trial1: Amir Jazaeri MD, Professor of Gynecologic Oncology at MD Anderson, and Emily Hinchcliff, MD, MPH, Assistant Professor of Obstetrics and Gynecology at Northwestern University Feinberg School of Medicine.

该临床试验基于观察到用免疫疗法治疗的OCCC患者的存活时间更长，所述免疫疗法的癌细胞具有导致PP2A减少的获得性基因突变。这项新试验的主要临床研究人员报告了这一发现1：安德森医学博士妇科肿瘤学教授Amir Jazaeri医学博士和西北大学芬伯格医学院妇产科助理教授Emily Hinchcliff医学博士。

The observation by Drs. Jazaeri and Hinchcliff, that a genetically acquired reduction in PP2A enhances sensitivity to immunotherapy, raises the possibility that reducing PP2A pharmacologically with LB-100 will enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody dostarlimab in patients with OCCC lacking the genetic reduction in PP2A.

Jazaeri博士和Hinchcliff博士观察到PP2A的遗传获得性减少增强了对免疫疗法的敏感性，这提高了用LB-100药理学减少PP2A将增强PD-1阻断单克隆抗体dostarlimab的抗肿瘤作用的可能性OCCC患者缺乏PP2A的基因减少。

John S. Kovach, M.D., LIXTE’s founder and Chi.

John S.Kovach，M.D.，LIXTE的创始人和Chi。